Alternativen zu Flaxseed

An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.

An FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.

An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended.

An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky.

Essential fatty acids critical for brain health, mood regulation, and reducing inflammation throughout the body.

Supports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.

Primary intracellular electrolyte that regulates blood pressure, nerve transmission, and muscle contraction — works in balance with sodium.

A lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.